- Biogen, Isis deal worth up to $299M for muscular atrophy drug
Biogen Idec agreed to pay $29 million upfront and possibly $45 million in milestone fees to secure a licensing option for Isis Pharmaceuticals' drug candidate for spinal muscular atrophy. If Biogen exercises that option, Isis is entitled to $225 million more as well as royalties upon commercialization. Bloomberg (1/4)        | Increase Productivity, Reduce R&D Spending
This webinar presents new concepts to improve productivity in the lab and discusses the challenges of implementing new technologies in the organic synthesis lab, their acceptance by chemists, and how a sustainable increase of productivity can be achieved. Register for the webinar. |
 - Athersys patents its stem cell heart treatments
Athersys has obtained a U.S. patent for its MultiStem technology, which uses multi-potent stem cells from adult bone marrow and other nonembryonic sources to treat various cardiac conditions. The patent covers multiple methods for delivering the stem cells. MedCityNews.com (1/4)  | Active Directory (AD) is the heart of your IT infrastructure, so a solid monitoring and backup and recovery solution is vital! In this Quest tech brief, discover best practices for protecting your AD environment, and how to understand — and resolve — performance problems in record time. |
  | At MetLife, Protecting Your Family Is Our Business
Even the most technical minds can find selecting the right life insurance policy to be a daunting task. Not anymore. MetLife makes it easy. Find rates as low as $14 per month for $250,000 of coverage, or $21 per month for $500,000 of coverage. Get a free, no-obligation quote today. |
 - Cornerstone gains hyponatremia drug with Cardiokine buyout
Cardiokine Biopharma was acquired by Cornerstone Therapeutics a day after the former submitted a new-drug application to the FDA for lead candidate lixivaptan. If approved, the drug will be used at hospitals to treat heart failure patients with hyponatremia. Cornerstone Chairman and CEO Craig Collard said lixivaptan complements the firm's neonatal lung surfactant Curosurf. MedCityNews.com (1/4)  | Download the latest Spotlight On… Melanoma report
This quarter’s Spotlight On… report focuses on Melanoma, which is currently experiencing an innovation breakthrough. The Spotlight On... report draws on the expert insight and strategic data from Thomson Reuters Pharma – the world's leading competitive intelligence solution. Download today. |
| Food & Agriculture |  |  | | - 2 British ministers support biotech foods
The U.K. needs to resume the debate about biotech food production if it really wants to address the issue of rising food costs, according to Mary Creagh, shadow secretary of environment, food and rural affairs. Farm minister Jim Paice expects biotech crops to be available to British farmers in the near future. Farmers Weekly Interactive (U.K.) (1/4) | Industrial & Environmental | | | | - Expiry of ethanol tax credit could lead to higher gas prices
Gasoline prices could increase by 4.5 cents beginning this week as a result of the expiration of the Volumetric Ethanol Excise Tax Credit. The tax credit's expiration, however, was not a big issue for the industry, as sound exports and the Renewable Fuel Standard ensure business for ethanol producers. "Things have changed. The marketplace has changed. Today, ethanol is 10% of the nation's gas supply," said Renewable Fuels Association Director of Public Affairs Matt Hartwig. USA TODAY (1/3) | News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This monthly e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the monthly BIOtechNOW e-newsletter.
| SmartQuote | | | |  | The vitality of thought is in adventure. Ideas won't keep. Something must be done about them."
--Alfred North Whitehead,
British mathematician and philosopher  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Wednesday, January 04, 2012
- Tuesday, January 03, 2012
- Friday, December 30, 2011
- Thursday, December 29, 2011
- Wednesday, December 28, 2011
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment